Dolasetron-d5

• Description:

  Dolasetron-d5 is deuterated labeled Dolasetron (HY-B0750) . Dolasetron (MDL-73147) is a 5-HT3 receptor antagonist with potential for treatment of chemotherapy-induced nausea and vomiting.

• Product Name Alternative:

  MDL-73147-d5

• UNSPSC:

  12352005

• Target:

  5-HT Receptor; Isotope-Labeled Compounds

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  GPCR/G Protein; Neuronal Signaling; Others

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(C1=C([2H])NC2=C1C([2H])=C([2H])C([2H])=C2[2H])O[C@@H]3C[C@@](CC4C5)([H])[N@](CC4=O)[C@@]5([H])C3

• Molecular Formula:

  C19H15D5N2O3

• Molecular Weight:

  329.40

• References & Citations:

  [1]Faria C, et al. Outcomes Associated with 5-HT3-RA Therapy Selection in Patients with Chemotherapy-Induced Nausea and Vomiting: A Retrospective Claims Analysis. Am Health Drug Benefits. 2014 Jan;7 (1) :50-8.|[2]Schwartzberg L, et al. Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) . Support Care Cancer. 2014 Feb;22 (2) :469-77.|[3]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported